Gradientech signs additional distribution agreement for Europe
The diagnostics company Gradientech today announces exclusive distribution agreements with the Triolab group for the commercialization of QuickMIC® in Sweden, Denmark, Norway, Iceland and the Baltics.
Triolab Group is the largest independent distributor and support organisation for clinical diagnostics and life science products in the Nordic and Baltic markets, representing many of the world’s leading suppliers. Triolab Group is part of AddLife.
“We are delighted to present Triolab as our distributor of our QuickMIC system for significant markets in Europe. The Triolab group is a strong partner with a very good reputation – known for its expertise, high-quality services and strong commitment to customer service”, says Sara Thorslund, CEO of Gradientech.
Gradientech already has an exclusive distribution agreement with Biomedica for the commercialization of QuickMIC® in Austria, Switzerland and Central Eastern Europe.
"By signing Triolab, being the leading distributor of the region in our market segment, we add another important piece in the foundation that will pivot us towards our goal of becoming the leading rapid AST solution”, says Peter Karlberg, VP Sales at Gradientech.
The QuickMIC system's ultra-rapid and precise results enable patients with sepsis to quickly receive specific personalized guidance of the right antibiotics in the right dose. The modular design makes it flexible and allows hospitals to start on a small scale and then scale up as needed.
“At Triolab group we want to secure that our customers have the possibility to use the most modern technology and give patients the best possible care. Sepsis is a life-threatening condition that develops as a reaction to infection and require emergency antibiotic therapy. As antibiotic resistance is a large and growing global threat and the current standard antibiotic susceptibility testing (AST) takes too long there is a need for faster diagnostics. We are therefore excited to start the collaboration with Gradientech to help hospitals provide rapid AST results in record-time, so that sepsis patients can receive proper targeted antibiotic treatment faster than ever before as well as fight antimicrobial resistance”, says Kai Rantanen, Head of the Board of Triolab Group.
For more information please contact:
Peter Karlberg, VP Sales Gradientech
Tel: + 46 763 29 08 14
peter.karlberg@gradientech.se
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80
sara.thorslund@gradientech.se
About Gradientech
Gradientech is leading the field of ultra-rapid antibiotic susceptibility testing. We develop next-generation diagnostics in infectious disease medicine. Our product QuickMIC allows patients with sepsis to quickly receive specific guidance on the right antibiotic in the right dose. It saves lives, reduces healthcare costs and limits the spread of antibiotic resistance – one of the greatest global health threats of our time. Gradientech is headquartered in Uppsala. Visit www.gradientech.se for more information.
About Triolab
Triolab Group is the largest independent distributor and support organisation for clinical diagnostics and life science products in the Nordics and Baltics (Denmark, Finland, Iceland, Norway, Sweden, Estonia, Latvia and Lithuania). It consists of 5 Triolab companies, which represent many of the world’s leading suppliers of diagnostic and life science products. Triolab Group is part of AddLife and the annual revenue is EUR 150 million. Over 70 of Triolab Group’s 160 employees work in sales, marketing and product support, almost 50 in technical support and over 30 in customer service.
